Skip to main content
. 2022 Sep 2;2022:7149686. doi: 10.1155/2022/7149686

Figure 4.

Figure 4

Peripheral blood samples from patients with non-small-cell lung cancer were obtained before any treatment and immediately processed in the circulating tumor cell (CTC) herringbone (HB)-chip that captures anti-EP-CAM-coated column epithelial cell adhesion molecules (left). Negative consumption of untargeted cells by a negative consumption method, including red blood cells and immune cells. Targeted cells such as CTCs were left in the chip for further analysis (right).